Pfizer Inc. (PFE) Misses On Revenue, Earnings, Lowers Guidance

Pfizer Inc. (PFE) Misses On Revenue, Earnings, Lowers Guidance
By Pfizer [Public domain], via Wikimedia Commons

Pfizer Inc. (NYSE:PFE) shares fell as much as 4 percent in pre-market trading after the company’s weak first-quarter earnings report. The company reported revenue of $13.5 billion, including revenues from Zoetis Inc (NYSE:ZTS), the veterinary medicine unit it spun off earlier this year through its own initial public offering. First-quarter revenue last year was $14.89 billion.

Play Quizzes 4
Pfizer Inc. (PFE) Misses On Revenue, Earnings, Lowers Guidance

First-quarter adjusted diluted earnings per share were 54 cents, and reported diluted earnings per share were 38 cents. Analysts were expecting the drug maker to report earnings of 55 cents per share on revenue of $14 billion. Pfizer Inc. (NYSE:PFE) attributed its earnings and revenue misses to the spinoff of Zoetis Inc (NYSE:ZTS) and also the stronger dollar.

The drug maker said it is continuing to consolidate its spin-off, retaining an 80.2 percent ownership interest. Shares of Zoetis Inc (NYSE:ZTS) actually rose more than 2 percent in pre-market trading after Pfizer announced its earnings.

Morningstar Investment Conference: Everything You Need To Know About Preferred Securities

Arena Investors Chilton Capital Management Schonfeld Strategic Advisors Robert Atchinson Phillip Gross favorite hedge fundsPreferred stock has been around for more than 150 years. One study suggests that the first shares of preferred stock were issued in 1836 by internal improvement companies in Maryland. However, some investors might not have given this asset class much thought until the government commandeered preferred shareholders' dividends in the government-sponsored enterprises Fannie Mae Read More

In addition, Pfizer Inc. (NYSE:PFE) cut its guidance for the full year, trimming earnings, excluding items, to between $2.14 and $2.24 per share and revenue to between $55.3 billion and $57.3 billion.

Pfizer Inc. (NYSE:PFE) announced a number of product developments along with its first-quarter guidance. It launched the stroke prevention drug Eliquis in the U.S., the U.K., Germany, Denmark and Japan. Its rheumatoid arthritis drug Xeljanz was approved for use in Japan, and a launch meeting for the drug was held in the U.S. in March. It launched ADHD drug Quillivant XR and received a reissued patent covering the well-known arthritis drug Celebrex.

During the first quarter, Pfizer Inc. (NYSE:PFE) also bought back $6.3 billion of its common stock.

Updated on

Michelle Jones is editor-in-chief for and has been with the site since 2012. Previously, she was a television news producer for eight years. She produced the morning news programs for the NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spent a short time at the CBS affiliate in Huntsville. She has experience as a writer and public relations expert for a wide variety of businesses. Email her at
Previous article Sirius XM Radio Inc (SIRI) Reports Record Revenue
Next article Office Depot Inc (ODP) Posts First-Quarter Net Losses Of $17 Million

No posts to display